Prognostic Significance of Homocysteine Level on Neurological Outcome in Brain Arteriovenous Malformations

Abstract

Objective. We aimed to investigate the serum homocysteine (Hcy) level in patients with brain arteriovenous malformation (bAVM) and their impact on neurological outcome during hospitalization. Method. We retrospectively reviewed patients diagnosed with bAVMs in Beijing Tiantan Hospital from January 2019 to August 2020. Patients were divided into two groups according to the mRS (modified Rankin Scale) score at discharge. Clinical and laboratory characteristics were compared. Logistic regression analyses were performed to identify the potential risk factors for short-term neurological outcome. Results. A total of 175 bAVM patients were enrolled in the study, including 139 patients with favorable outcome ( $\text{mRS}\le 2$ ) and 36 patients with unfavorable outcome ( $\text{mRS}>2$ ). Hyperhomocysteinemia was identified in 32.6% of cases ( $n=57$ ). Serum Hcy level was related to seizure manifestation ( $P=0.034$ ) and short-term neurological outcome ( $P=0.027$ ). Logistic regression analysis showed that serum glucose (OR 1.897, 95% CI 1.115-3.229; $P=0.018$ ) and Hcy level (OR 0.838, 95% CI 0.720-0.976; $P=0.023$ ) were significantly associated with short-term disability. Conclusion. Our results indicated that the lower serum Hcy level is strongly associated with in-hospital unfavorable outcome. Further prospective studies of Hcy natural history and managements in bAVMs are required, which would be valuable for evaluating the disease-modifying efficacy of oral nutritional supplements in bAVM patients.